We tested 4′-epi-doxorubicin (epirubicin) in 15 patients with advanced squamous cell carcinoma of the head and neck which progressed after conventional therapy. The drug was administered at the dosage of 25 mg/m2 weekly. No patient achieved objective response. Toxicity was minimal. Epirubicin given at this dose and schedule revealed no activity in heavily pretreated patients with cancer of the head and neck.
Get full access to this article
View all access options for this article.
References
1.
ArcamoneF., PencoS., VigevaniA., RedaelliS., FranchiF.: Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.J. Med. Chem., 18: 703–707, 1975.
2.
BerettaG., RattiD., TedeschiL., FraschiniP., LuporiniG.: Epirubicin studies with low weekly dose.Proc. 13th Intern. Congress of Chemotherapy, 259/53–55, Vienna, 1983.
3.
BonfanteV., BonadonnaG., VillaniF., Di FronzoG., MartiniA., CasazzaA.M.: Preliminary phase I study of 4′-epi-adriamycin.Cancer Treat. Rep., 63: 915–918, 1979.
4.
CasazzaA.M., GiulianiF.C.: Preclinical studies of epirubicin. In: Advances in Anthracycline Chemotherapy: Epirubicin.BonadonnaG. (ed.), pp. 31–40, Masson, Milan, 1984.
5.
GanzinaF.: 4′-Epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data.Cancer Treat. Rev., 10: 1–22, 1983.
6.
HongW.K., BromerR.: Chemotherapy in head and neck cancer.N. Engl. J. Med., 308: 75–79, 1983.
7.
JonesW.S., MattssonW.: Phase II study of weekly low-dose of 4′-epi-doxorubicin in advanced postmenopausal breast cancer.Cancer Treat. Rep., 68: 675–677, 1984.
8.
KishJ., DrelichmanA., JacobsJ., HoschenerJ., KinzieJ., LohJ., WeaverA., Al-SarrafM.: Clinical trials of cisplatin and 5-FU infusions as initial treatment for advanced squamous cell carcinoma of the head and neck.Cancer Treat. Rep., 66: 471–474, 1982.
9.
MageeM.J., HowardJ., BoslG.J., WittesR.E.: Phase II trial of 4′-epi-doxorubicin in advanced carcinoma of head and neck origin.Cancer Treat. Rep., 69: 125–126, 1985.
10.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
11.
MuggiaF.M., GreenM.D.: Special modes of administration. In: Advances in Anthracycline Chemotherapy: Epirubicin.BonadonnaG. (ed.), pp. 149–152, Masson, Milan, 1984.
12.
Robustelli Delia CunaG., PretiP., CuzzoniQ., PavesiL., StradaM.R., BernardoG., GanzinaF., IntiniC.: Epirubicin plus cisplatinum in the treatment of advanced head and neck cancer. In: Advances in Anthracycline Chemotherapy: Epirubicin.BonadonnaG. (ed.), pp. 155–163, Masson, Milan, 1984.
13.
RooneyM., KishJ., JacobsJ., KinzieJ., WeaverA., CrissmanJ., Al-SarrafM.: Improved complete response and survival in advanced head and neck cancer after three-course induction therapy with 120 hours 5-FU infusion and cisplatin.Cancer, 55: 1123–1128, 1985.
14.
ShauerP., WittesR., GrallaR., CasperE.S., YoungC.W.: A phase I trial of 4′-epi-adriamycin.Cancer Clin. Trials, 4: 433–437, 1981.
15.
WeaverA., FlemingS., VandenbergH.: Cisplatinum and 5-fluorouracil on initial therapy in advanced epidermoid cancers of the head and neck.Head Neck Surg., 4: 370–373, 1982.
16.
YoungC.W., MageeM.J., HowardJ., BoslG.L., WittesR.E.: Phase II assessment of epirubicin in head and neck cancer. In: International symposium « Advances in Anthracycline Chemotherapy: Epirubicin ».Farmitalia Carlo Erba, p. 19, Milan, June 10–12, 1984.
